1. "2017"
Formats
  1. Journal Article (3053)
  2. Meeting Abstract (1581)
  3. Book Section (242)
  4. Conference Paper (35)
  5. Book Whole (12)
  6. Editorial (1)
  7. Review (1)
Groups
  1. Department of Medicine (2037)
  2. GSK Faculty (1130)
  3. Solid Tumor Oncology Division (1105)
  4. Sloan Kettering Institute Postdocs (1022)
  5. Surgery (893)
  6. Survivorship Research (780)

More Groups

People
  1. Sergio Giralt (86)
  2. Jose Baselga (68)
  3. Michael Berger (67)
  4. Monica Morrow (65)
  5. Jedd Wolchok (62)
  6. Martin Tallman (61)

More People

Years
  1. 2017 (4925)
Publications
  1. Journal of Clinical Oncology (349)
  2. Blood (233)
  3. Annals of Oncology (123)
  4. International Journal of Radiation Oncology, Biology, Physics (122)
  5. Modern Pathology (85)
  6. Laboratory Investigation (76)

More Publications

Publishers
  1. Elsevier Inc. (599)
  2. Springer (383)
  3. American Society of Clinical Oncology (378)
  4. Nature Publishing Group (310)
  5. Oxford University Press (280)
  6. American Society of Hematology (246)

More Publishers

Results (4925)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Discovery of candidate predictors of response to tazemetostat in diffuse large B-cell lymphoma and follicular lymphoma using NGS technology on ctDNA samples collected pre-treatment
    Meeting Abstract

    Daigle, S.; McDonald, A. A.; Morschhauser, F.; Salles, G.; Ribrag, V.; McKay, P.; Tilly, H.; Schmitt, A.; Gerecitano, J.; Fruchart, C.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • LSD1 inhibition exerts its anti-leukemic effect by recommissioning PU.1-and C/Ebpα-dependent enhancers in AML
    Meeting Abstract

    Cusan, M.; Cai, S.; Mohammad, H. P.; Krivtsov, A. V.; Chramiec, A.; Loizou, E.; Tenen, D. G.; Ye, M.; Will, B.; Steidl, U. G.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • High dose cyclophosphamide and pre-treatment disease burden dictate response and survival in a multicenter clinical trial using CD19-specific CAR T cells for relapsed/refractory B-ALL
    Meeting Abstract

    Curran, K. J.; Margossian, S. P.; Kernan, N. A.; Silverman, L. B.; Park, J. H.; Sauter, C. S.; Smith, E. L.; Boulad, F.; Cancio, M. I.; Forlenza, C.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Nivolumab treatment beyond investigator-assessed progression: Outcomes in patients with relapsed/refractory classical Hodgkin lymphoma from the phase 2 CheckMate 205 study
    Meeting Abstract

    Cohen, J. B.; Engert, A.; Ansell, S. M.; Younes, A.; Trneny, M.; Savage, K. J.; Ramchandren, R.; Collins, G.; Fanale, M. A.; Armand, P.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Brentuximab vedotin plus doxorubicin, vinblastine, dacarbazine (A+AVD) as frontline therapy demonstrates superior modified progression-free survival versus ABVD in patients with previously untreated stage III or IV Hodgkin lymphoma (HL): The phase 3 ECHELON-1 study
    Meeting Abstract

    Connors, J. M.; Jurczak, W.; Straus, D. J.; Ansell, S. M.; Kim, W. S.; Gallamini, A.; Younes, A.; Alekseev, S.; Illes, A.; Picardi, M.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Ibrutinib therapy in patients with relapsed/refractory marginal zone lymphoma: Analysis by prior rituximab treatment and baseline mutations
    Meeting Abstract

    Chen, R.; de Vos, S.; Thieblemont, C.; Martin, P.; Flowers, C.; Morschhauser, F.; Collins, G.; Ma, S.; Coleman, M.; Peles, S.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Characterizing ionizing radiation exposure after T-cell depleted allogeneic hematopoietic cell transplantation
    Meeting Abstract

    Cho, C.; Maloy, M.; Devlin, S. M.; Aras, O.; Castro-Malaspina, H. R.; Dauer, L. T.; Jakubowski, A. A.; O'Reilly, R. J.; Papadopoulos, E. B.; Perales, M. A.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Targeting the DNA damage response pathway in MLL- rearranged B-acute lymphoblastic leukemias
    Meeting Abstract

    Chu, S. H.; Song, E. J.; Chabon, J.; Minehart, J.; Feng, Z.; Ross, K.; Koche, R.; Krivtsov, A. V.; Armstrong, S.
    Blood (2017)

    Fulltext@MSK | Save
  • CD99 regulates normal and malignant stem cell function by restricting protein translation
    Meeting Abstract

    Chung, S. S.; Hu, W.; Guo, L.; Kannan, L.; Levine, R. L.; Park, C. Y.
    Blood (2017)

    Fulltext@MSK | Save
  • Targeted deep sequencing in untreated progressive CLL helps to better dissect the genomic landscape and shows novel associations between mutations, prognostic and clinical parameters: Data from E1912, a randomized phase III study of the ECOG-ACRIN cancer research group
    Meeting Abstract

    Braggio, E.; Wang, V.; Bruins, L. A.; Barrio, S.; Lesnick, C.; Barrientos, J. C.; O'Brien, S. M.; Tallman, M. S.; Litzow, M. R.; Fonseca, R.; more...
    Blood (2017)

    Fulltext@MSK | Save